Periprocedural myocardial injury according to optical characteristics of neointima and treatment modality of in-stent restenosis.
Coronary Angiography
/ adverse effects
Coronary Restenosis
/ diagnosis
Coronary Vessels
/ pathology
Drug-Eluting Stents
/ adverse effects
Heart Injuries
/ complications
Humans
Neointima
Percutaneous Coronary Intervention
/ adverse effects
Stents
/ adverse effects
Tomography, Optical Coherence
Treatment Outcome
Drug-eluting balloon
Drug-eluting stent
In-stent restenosis
Neointimal characterization
Optical coherence tomography
Periprocedural myocardial injury
Journal
Clinical research in cardiology : official journal of the German Cardiac Society
ISSN: 1861-0692
Titre abrégé: Clin Res Cardiol
Pays: Germany
ID NLM: 101264123
Informations de publication
Date de publication:
Jul 2022
Jul 2022
Historique:
received:
28
01
2022
accepted:
06
04
2022
pubmed:
28
4
2022
medline:
2
7
2022
entrez:
27
4
2022
Statut:
ppublish
Résumé
Aim of the present study was to investigate the impact of increasing neointimal inhomogeneity and neoatherosclerosis as well as of treatment modality of in-stent restenosis (ISR) on the occurrence of periprocedural myocardial injury (PMI). Patients with normal or stable/falling increased baseline high-sensitivity troponin T (hs-cTnT) undergoing intravascular optical coherence tomography (OCT) and subsequent percutaneous coronary intervention (PCI) of ISR by means of drug-coated balloon (DCB) or drug-eluting stent (DES) were included. Overall, 128 patients were subdivided into low (n = 64) and high (n = 64) inhomogeneity groups, based on the median of distribution of non-homogeneous quadrants. No significant between-group differences were detected in terms of hs-cTnT changes (28.0 [12.0-65.8] vs. 25.5 [9.8-65.0] ng/L; p = 0.355), or the incidence of major PMI (31.2 vs. 31.2%; p = 1.000). Similarly, no differences were observed between DCB- and DES-treated groups in terms of hs-cTn changes (27.0 [10.0-64.0] vs. 28.0 [11.0-73.0] ng/L; p = 0.795), or the incidence of major PMI (28.9 vs. 35.6%; p = 0.566). Additionally, no significant interaction was present between optical neointimal characteristics and treatment modality in terms of changes in hs-cTnT (P In patients undergoing PCI for ISR, there was no association between increasing neointimal inhomogeneity, or increasing expression of neoatherosclerotic changes and occurrence of PMI. PMI occurrence was not influenced by the treatment modality (DCB vs. DES) of ISR lesions, a finding that supports the safety of DCB treatment for ISR.
Identifiants
pubmed: 35476138
doi: 10.1007/s00392-022-02024-z
pii: 10.1007/s00392-022-02024-z
pmc: PMC9242953
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
827-837Informations de copyright
© 2022. The Author(s).
Références
Clin Res Cardiol. 2019 Sep;108(9):1059-1068
pubmed: 30783752
Int J Cardiovasc Imaging. 2016 Oct;32(10):1483-94
pubmed: 27423209
Eur Heart J. 2015 Dec 14;36(47):3320-31
pubmed: 26417060
Eur Heart J. 2019 Jan 7;40(2):87-165
pubmed: 30165437
EuroIntervention. 2021 Aug 06;17(5):e388-e395
pubmed: 32894230
Coron Artery Dis. 2018 May;29(3):237-245
pubmed: 29215469
Catheter Cardiovasc Interv. 2015 Mar;85(4):564-72
pubmed: 25158217
JACC Cardiovasc Interv. 2016 Dec 26;9(24):2511-2523
pubmed: 27889345
Rev Esp Cardiol (Engl Ed). 2016 Aug;69(8):746-53
pubmed: 27230475
Nat Rev Cardiol. 2014 Jan;11(1):13-23
pubmed: 24189405
Eur Heart J. 2021 Jul 15;42(27):2630-2642
pubmed: 34059914
Eur Heart J. 2021 Jan 21;42(4):323-334
pubmed: 33257958
JACC Cardiovasc Interv. 2019 Oct 14;12(19):1954-1962
pubmed: 31601389
Circulation. 2018 Nov 13;138(20):e618-e651
pubmed: 30571511
Eur Heart J. 2018 Apr 1;39(13):1100-1109
pubmed: 29365133
EuroIntervention. 2017 Oct 20;13(8):962-969
pubmed: 28134126
J Am Coll Cardiol. 2020 Sep 29;76(13):1521-1531
pubmed: 32972528
J Am Coll Cardiol. 2016 Nov 29;68(21):2259-2268
pubmed: 27884243
Circ Cardiovasc Interv. 2011 Aug;4(4):378-86
pubmed: 21791670
J Am Coll Cardiol. 2013 Oct 22;62(17):1563-70
pubmed: 24135581